Head of Musculoskeletal Diseases
Scientific Leadership
Nordic Bioscience
Denmark
Kim Henriksen joined Nordic Bioscience in 2002 and assumed the position as Head of Muscoloskeletal Diseases 2011. Kim’s research has focused primarily on three areas; i) the development of novel therapeutic peptides for the indications: type 2-diabetes, obesity and NASH, which has research has resulted in several peptide candidates in preclinical development and 1 in clinical testing and ii) the potential of protein fragments as biomarkers of both musculoskeletal diseases and, more recently, neurodegenerative diseases, which has resulted in assays measuring degradation of tau in blood, which are being explored for their prognostic ability within dementias.
Type 2-diabetes, obesity and NASH